STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRNX
  4. [8-K] Crinetics Pharmaceuticals, Inc. Reports Material Event

Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. reports further progress toward its planned acquisition by Vertex Pharmaceuticals. The Hart-Scott-Rodino waiting period for the merger expired at 12:45 p.m. Eastern Time on August 12, 2026, and required antitrust approvals in Austria, Germany and Australia have been received, with an Australian waiting period scheduled to expire on August 27, 2026 at 9:59 a.m. Eastern Time.

The merger still depends on remaining closing conditions, including adoption of the merger by Crinetics’ shareholders at a special meeting on August 28, 2026. Assuming shareholder approval, the companies expect the merger and related transactions to close in early September 2026. Crinetics highlights extensive forward‑looking risks and directs shareholders to its definitive proxy statement filed July 31, 2026 for detailed information.

Positive

  • None.

Negative

  • None.

Filing Explained

If completed, the merger would leave Crinetics as Vertex’s wholly owned subsidiary after Merger Sub merges into it; the transaction remains incomplete.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
HSR Act waiting period expiration 12:45 p.m. Eastern Time on August 12, 2026 Expiration of the U.S. Hart-Scott-Rodino waiting period for the merger
Australian waiting period expiration August 27, 2026 at 9:59 a.m. Eastern Time Scheduled expiration of a waiting period under applicable Australian antitrust laws
Shareholder meeting date August 28, 2026 Special meeting of Crinetics’ shareholders to vote on adoption of the merger
Potential annual revenue more than $5 billion Vertex’s stated expectation for annual revenue potential related to the transactions
Accretive timing target 2029 Vertex’s expectation that the transactions will become accretive to non-GAAP operating income
Definitive proxy filed July 31, 2026 Date Crinetics filed and commenced mailing its definitive proxy statement
Hart-Scott-Rodino Antitrust Improvements Act of 1976 regulatory
"The waiting period with respect to the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976"
waiting period regulatory
"subject to, among other things, the expiration or termination of the waiting period under the HSR Act"
A waiting period is a legally required pause before a corporate action — such as a securities offering, merger, or regulatory approval — can take effect, giving regulators time to review documents and the public time to respond. It matters to investors because it sets when money can change hands and when shares can be traded, creating a window of uncertainty and opportunity much like a cooling-off period before a big purchase.
definitive proxy statement regulatory
"Crinetics filed with the Securities and Exchange Commission a definitive proxy statement"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
non-GAAP operating income financial
"expectations that the Transactions will become accretive to non-GAAP operating income in 2029"
Non-GAAP operating income is a measure of a company's profit from its core business activities, calculated by excluding certain expenses or income that are not part of regular operations. It provides a clearer picture of how well the business is performing by focusing on ongoing operations, helping investors compare companies more consistently and make better-informed decisions.
fully committed bridge financing financial
"expectations for Vertex’s financing of the Transactions, including support by the fully committed bridge financing"

FAQ

What merger progress did Crinetics (CRNX) announce with Vertex Pharmaceuticals?
Crinetics announced that the HSR Act waiting period expired on August 12, 2026 and that required antitrust approvals in Austria, Germany and Australia have been received, moving the planned merger with Vertex closer to potential closing.

When is the Crinetics (CRNX) shareholder vote on the Vertex merger?
Crinetics states that its shareholders are scheduled to vote on the Vertex merger at a special meeting on August 28, 2026. Adoption of the merger by shareholders remains a key closing condition before the transaction can be completed.

When do Crinetics and Vertex expect the merger to close?
Assuming shareholder approval and satisfaction of remaining conditions, Crinetics and Vertex expect the merger to close in early September 2026. This timing remains subject to completion of all closing conditions described in the merger agreement.

What antitrust milestones affecting Crinetics (CRNX) have been reached for the Vertex deal?
The companies report that the U.S. HSR waiting period expired on August 12, 2026 and that approvals in Austria, Germany and Australia have been received, with an Australian waiting period scheduled to expire on August 27, 2026.

Where can Crinetics (CRNX) investors find detailed information about the Vertex merger?
Crinetics filed a definitive proxy statement on July 31, 2026 and began mailing it to shareholders the same day. Investors can access it via the SEC’s website or the Investors section of Crinetics’ website for full transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2026

Crinetics Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)


Delaware
001-38583
26-3744114
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
     
6055 Lusk Boulevard
    
San Diego, California
  
92121
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 450-6464
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.001 per share
  
CRNX
  
Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously announced, on July 6, 2026, Crinetics Pharmaceuticals, Inc., a Delaware corporation (“Crinetics” or the “Company”), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Vertex”), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Vertex (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Merger Sub will be merged with and into Crinetics (the “Merger”), with Crinetics surviving the Merger as a wholly owned subsidiary of Vertex.

The completion of the Merger is subject to, among other things, (i) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and (ii) the termination, expiration or receipt, as applicable, of the waiting periods, approvals, clearances and consents required under applicable antitrust laws in Austria, Germany and Australia.

The waiting period with respect to the Merger under the HSR Act expired at 12:45 p.m. Eastern Time on August 12, 2026. In addition, as of August 13, 2026, the approvals required under applicable antitrust laws in Austria, Germany and Australia with respect to the Merger have been received (subject to the expiration of a waiting period under applicable antitrust laws in Australia that is currently scheduled to expire on August 27, 2026 at 9:59 a.m. Eastern Time). The Merger remains subject to other closing conditions, including the adoption of the Merger by Crinetics’ shareholders. Assuming adoption of the Merger by Crinetics' shareholders at a special meeting of shareholders on August 28, 2026, the Merger and the other transactions contemplated by the Merger Agreement (collectively, the “Transactions”) are expected to close in early September 2026.

Cautionary Notice Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 related to Crinetics, Vertex and the Transactions that are subject to risks, uncertainties and other factors. While Crinetics believes the forward-looking statements contained in this Current Report on Form 8-K are accurate, these forward-looking statements represent the beliefs of Crinetics only as of the date of this Current Report on Form 8-K, and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies and members of their senior management teams. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements may relate to, but are not limited to: the benefits of Vertex’s proposed acquisition of Crinetics and associated integration plans; the expected timing of the completion of the Transactions; the commercial potential of PALSONIFY and the anticipated potential of atumelnant and Crinetics’ other pipeline assets, including the potential for PALSONIFY to redefine the treatment paradigm in acromegaly and for atumelnant to become the leading therapy for people struggling with CAH; expectations that the Transactions will accelerate Vertex’s revenue growth and enhance Vertex’s long-term earnings profile, including the potential for more than $5 billion in annual revenue, and support Vertex’s goal of sustained double digit revenue growth; expectations that the Transactions will become accretive to non-GAAP operating income in 2029; expectations for Vertex’s financing of the Transactions, including support by the fully committed bridge financing; and any assumptions underlying any of the foregoing.

Forward-looking statements are subject to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: the occurrence of any event or circumstance that could give rise to the right of Crinetics or Vertex to terminate the Merger Agreement, including circumstances requiring payment of a termination fee pursuant to the Merger Agreement; the risk that the Transactions may not close in the anticipated timeframe or at all due to one or more of the other closing conditions not being satisfied or waived; the possibility that competing offers will be made; the risk that there may be unexpected costs, charges or expenses resulting from the Transactions; risks related to the ability of Crinetics and Vertex to successfully integrate the businesses and the possibility that integration may be more difficult, time consuming or costly than expected; risk that the Transactions disrupt Crinetics’ or Vertex’s current plans and operations; the risk that certain restrictions during the pendency of the Transactions may impact Crinetics’ ability to pursue certain business opportunities or strategic transactions; risks related to disruption of each company’s management’s time and attention from ongoing business operations due to the Transactions; the risk that any announcements relating to the Transactions could have adverse effects on the market price of Crinetics’ and/or Vertex’s common stock, credit ratings or operating results; the risk of litigation that could be instituted against the parties or their respective directors, managers or officers and/or regulatory actions related to the Transactions, including the effects of any outcomes related thereto; the effects of the Transactions on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the impact of competitive products and pricing; that Vertex may not realize the potential benefits of the Transactions; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; and actual or contingent liabilities related to the Transactions. In addition, the product candidates being developed by Crinetics are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these product candidates will be commercially successful. Forward-looking statements in this Current Report on Form 8-K should be evaluated together with the many uncertainties that affect Vertex’s and Crinetics’ businesses, particularly those risks listed under the heading “Risk Factors” and the other cautionary factors discussed in the parties’ periodic reports filed with the SEC, including Vertex’s and Crinetics’ annual reports on Form 10-K for the year ended December 31, 2025, and quarterly reports on Form 10-Q and current reports on Form 8-K, all of which are available on the SEC’s website at www.sec.gov. Undue reliance should not be placed on these statements. All forward-looking statements are based on information currently available to Crinetics, and Crinetics disclaims any obligation to update the information contained in this Current Report on Form 8-K as new information becomes available, except as required by law.

Additional Information and Where to Find It

This Current Report on Form 8-K is being made in respect of the proposed transaction between Crinetics and Vertex. In connection with the proposed transaction between Crinetics and Vertex, Crinetics filed with the Securities and Exchange Commission a definitive proxy statement with the SEC on July 31, 2026 and commenced mailing to Crinetics’ shareholders on July 31, 2026. This communication is not a substitute for the proxy statement or any other document that may be filed by Crinetics with the SEC. BEFORE MAKING ANY DECISION, COMPANY SHAREHOLDERS ARE URGED TO CAREFULLY READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT BECAUSE THEY DO AND WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Any vote in respect of resolutions to be proposed at Crinetics’ stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Crinetics’ proxy statement. You will be able to obtain a free copy of the proxy statement and other related documents (when available) filed by Crinetics with the SEC at the website maintained by the SEC at www.sec.gov or by accessing the Investors section of Crinetics’ website at https://ir.crinetics.com.

No Offer or Solicitation

This Current Report on Form 8-K is for informational purposes only and is not intended to, and does not constitute or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
Crinetics Pharmaceuticals, Inc.
     
Date: August 14, 2026
By:
/s/ R. Scott Struthers, Ph.D.
   
R. Scott Struthers, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents